Acrivon Therapeutics
Clinical-stage precision oncology powered by AP3 phosphoproteomics
About Acrivon Therapeutics
Funding & Growth
✓ Pros
- • Direct line of sight from analysis to drug development decisions
- • Public company stage with equity
- • Phosphoproteomics-first scientific approach is differentiated
- • Small team — high autonomy and influence
✗ Cons
- • Clinical-stage volatility (trial outcomes drive valuation)
- • Watertown commute (no major remote policy advertised)
- • Smaller engineering function than at larger biotechs
🏢 Working Here
Acrivon is a clinical-stage precision oncology company built around the AP3 (Acrivon Predictive Precision Proteomics) platform — a phosphoproteomics-based approach to predicting patient response to targeted cancer therapies.
The computational team works at the intersection of mass spec data, proteomics, and clinical outcomes, with a strong emphasis on translating signals from the AP3 platform into patient stratification for clinical trials.
As a public company at the early commercial stage, the work tends to be high-stakes and tightly coupled to active trials — bioinformaticians here are close to the science and influence drug development decisions directly.
🧬 Bioinformatics Focus
Acrivon's bioinformatics work centers on quantitative phosphoproteomics data analysis from mass spectrometry, statistical methods for identifying drug response biomarkers in patient samples, pathway and network analysis to map drug mechanism of action, and integration of proteomics signals with genomic and clinical data.
The team supports the AP3 platform across drug discovery, biomarker validation, and clinical trial patient selection.
Roles typically require strong proficiency with R or Python, experience with proteomics workflows (Proteome Discoverer, MaxQuant, Skyline), and familiarity with clinical translational research.